# Pizarra — PT-pseudo_c03b1168ff4d (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_c03b1168ff4d
Task: 1

Encounter: Urology - outpatient on 05 Jan 2025.
Referrer: Dr. E. Mulder (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 74-year-old male
  - PSA: 7.8 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.165 ng/mL²
  - PSA velocity: 1.2 ng/mL/yr
  - Prior PSA: 6.3 ng/mL
  - Prostate volume: 47.17 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.75055045 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Hypercholesterolaemia, Chronic kidney disease
  - Problem list / PMHx: Hypertension, Hypercholesterolaemia, Chronic kidney disease
  - Current medication: valsartan, lisinopril, atorvastatin, simvastatin, rosuvastatin
  - Allergies: NKA
  - Additional notes: PSA 7.8 ng/mL. PI-RADS 4. PSAD 0.17. Prostate volume 47 mL. csPCa 0.75.

Vitals: weight 87 kg, height 184 cm, BMI 25.7, BP 143/82 mmHg, HR 81 bpm. Smoking: Ex-smoker (34 pack-yr, quit 2006).

Chief complaint: Rising PSA levels combined with a previous positive biopsy mandate a current clinical reassessment.

History: A confirmed prostate malignancy now requires surveillance, following initial PSA investigation in mid-2022. The subject is a 74-year-old ICT consultant who remains married and resides alone, though his adult son lives in close proximity. Tobacco use ceased in 2006, following a 34 pack-year accumulation. Physical activity remains high, comprising three weekly five-kilometre runs, with no alcohol consumption. Distance to the clinic exceeds 90 minutes, and telephone consultations are preferred. Lower urinary tract symptoms are pronounced, yielding an IPSS score of 26. Hypertension, hypercholesterolaemia, and chronic kidney disease form the background of his medical history. Current pharmacotherapy consists of valsartan, lisinopril, atorvastatin, simvastatin, and rosuvastatin. Recent preventive care included a routine colonoscopy and audiology evaluation, while his latest cardiology review returned unremarkable.

Physical examination: Digital rectal examination yields normal findings: a symmetrically enlarged gland with a smooth, firm consistency and no palpable nodules or asymmetry. Vital sign measurements record 143/82 mmHg for blood pressure and 81 bpm for heart rate. A general physical assessment notes a BMI of 25.7, alongside clear pulmonary fields, a regular cardiac rhythm, and an absence of peripheral oedema.

Patient info: ICT consultant; Married; Lives alone; adult son nearby.
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Running 3x/week, 5 km; IPSS score: 26/35 (severe LUTS).

Recent other appointments: Gastroenterology — surveillance colonoscopy; Audiology — hearing test.
Admin: Lives >90 min from clinic; phone follow-up preferred where clinically safe.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.56 +/- 0.20   (95% CI 0.17-0.91)

Where the uncertainty comes from:
  - aleatoric  dA = 0.16  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.13  (few labelled cases resemble this one)
  - 6.6 effective neighbours out of 10; 3 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no, yes}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=4.0, bx_ord=3.0, psa=7.8, age=74.0, psad=0.165, dre_ord=0.0, vol=47.17, n_pmhx=3.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender only used the structured panel. It could not weigh the PSA velocity (1.2 ng/mL/yr) against the prior PSA (6.3 ng/mL) to assess the rate of rise, which is a critical dynamic factor. It also did not see the full mpMRI report details beyond the PI-RADS 4 score, nor the specific trend in the PSA history, which is crucial for risk stratification. Finally, it did not see the full laboratory panel, which might contain markers relevant to the patient's CKD or other comorbidities influencing risk.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests 'BIOPSY' with a wide interval ($\pm 0.20$). This wide interval suggests the classifier is uncertain, which could be due to the epistemic term ($dA = 0.13$) indicating few similar cases. A failure mode is the contradiction between the high csPCa predicted probability (0.75055045) and the normal DRE findings, which might suggest a benign process despite the high PSA/PI-RADS. Another failure mode is that the prior ignores the PSA velocity (1.2 ng/mL/yr), which indicates a concerning trend, potentially overriding the PI-RADS 4 score if the rate of change is highly aggressive.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report details suggest a high likelihood of clinically significant cancer despite PI-RADS 4, it would increase the need for biopsy.
  <document> PSA history (trend) -> If the trend shows a very rapid rise, it would increase the need for biopsy.
  <document> laboratory results (full panel) -> If lab results show markers that significantly alter the risk profile (e.g., specific tumor markers or renal function changes), it would modify the decision.
  <document> previous GP / urology consultation notes -> These notes might contain context regarding the initial diagnosis or surveillance plan that informs the current decision.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line.

  **radiology / mpMRI report**
  {"case_id": "PT-pseudo_c03b1168ff4d", "radiology_report": "Spaarne Gasthuis (Haarlem) Radiology | 18 December 2024 | Multiparametric MRI of the Prostate\nClinical Indication: Reassessment due to rising PSA value: 7.8 ng/mL and a previous positive biopsy.\n\nFINDINGS:\nThe gland measures 47.17 mL in total volume. T2-weighted sequences identify an asymmetric hypointense area within the left peripheral zone spanning the base to mid section, sized roughly 14 x 11 x 16 mm. DWI reveals restricted diffusion with matching low ADC signal, categorizing this finding as PI-RADS: 4. DCE sequences highlight early focal enhancement against the background parenchyma. Seminal vesicles appear normal. There is no evidence of extracapsular extension or suspicious lymphadenopathy.\n\nIMPRESSION:\nPI-RADS: 4 lesion located in the left peripheral zone (base/mid).\nProstate volume: 47.17 mL; PSA density: 0.165 ng/mL/mL.\ncsPCa probability: 0.75055045."}

  **psa_trend**
  {"case_id": "PT-pseudo_c03b1168ff4d", "psa_trend": [{"date": "Jun 2022", "val": 1.5}, {"date": "Sep 2023", "val": 3.4}, {"date": "Jan 2025", "val": 7.8}]}

  **lab_results**
  {"case_id": "PT-pseudo_c03b1168ff4d", "laboratory_results": [{"name": "PSA", "val": "7.8 ng/mL", "date": "14 Dec 2024", "flag": "H"}, {"name": "Free PSA", "val": "1.59 ng/mL", "date": "14 Dec 2024", "flag": ""}, {"name": "%Free PSA", "val": "20%", "date": "14 Dec 2024", "flag": ""}, {"name": "Haemoglobin", "val": "14.8 g/dL", "date": "14 Dec 2024", "flag": ""}, {"name": "WBC", "val": "6.9 x10^9/L", "date": "14 Dec 2024", "flag": ""}, {"name": "Platelets", "val": "279 x10^9/L", "date": "14 Dec 2024", "flag": ""}, {"name": "Creatinine", "val": "136 umol/L", "date": "14 Dec 2024", "flag": "H"}, {"name": "eGFR", "val": "<60 mL/min/1.73m2", "date": "14 Dec 2024", "flag": "L"}, {"name": "Testosterone", "val": "9.4 nmol/L", "date": "14 Dec 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "82 U/L", "date": "14 Dec 2024", "flag": ""}, {"name": "LDH", "val": "213 U/L", "date": "14 Dec 2024", "flag": ""}, {"name": "HbA1c", "val": "6.6 %", "date": "14 Dec 2024", "flag": ""}]}

  **previous_notes**
  {"case_id": "PT-pseudo_c03b1168ff4d", "previous_notes": [{"date": "16 Jan 2023", "author": "Dr. E. Mulder (GP)", "text": "16 January 2023 | Dr. E. Mulder (GP): Initial consultation occurred after a June 2022 PSA reading of 6.1 ng/mL. Subsequent testing confirmed the elevation, leading to a urology referral and a biopsy that returned positive for malignancy. Renal function and lipid profiles continue to be tracked alongside his specialist care. Due to residing outside our primary service area, routine telephone check-ins have been arranged."}, {"date": "07 Sep 2024", "author": "Dr. E. Mulder (GP)", "text": "07 September 2024 | Dr. E. Mulder (GP): Ongoing monitoring for established prostate cancer. A September 2023 PSA measurement recorded 6.3 ng/mL, with the most recent December 2024 result reaching 7.8 ng/mL. Blood pressure and lipid levels remain well controlled. Remote communication is preferred given the significant travel distance to the clinic."}]}

NOT RETRIEVED
  get_family_history - Not called as per retrieval economy rules.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  - PSA velocity of 1.2 ng/mL/yr, indicating a concerning trend.
  - mpMRI finding of PI-RADS 4 lesion in the left peripheral zone with restricted diffusion.
  - csPCa predicted probability of 0.75055045.
  - PSA has risen from 6.3 ng/mL (Sep 2023) to 7.8 ng/mL (Jan 2025).

  AGAINST sampling this patient now:
  - Digital Rectal Examination yields normal findings (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done).

WHERE THIS LEANS
  The retrieved evidence strongly supports further investigation due to the combination of a concerning PSA velocity, a PI-RADS 4 lesion identified on MRI, and a high predicted cancer probability. This leans toward the statistical prior's suggestion of BIOPSY, as the dynamic and imaging data align with increased suspicion.

[Sections actually revealed in this consultation: radiology_report, psa_trend, laboratory_results, previous_notes. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended because the evidence converges on further investigation due to multiple concerning factors. The PI-RADS 4 lesion in the left peripheral zone, combined with a rising PSA velocity of 1.2 ng/mL/yr and a high csPCa probability of 0.75, strongly supports sampling. The PSA has risen from 6.3 ng/mL to 7.8 ng/mL, and the PSA density of 0.165 ng/mL/mL is elevated, which together mandate a biopsy.

Variables that carried weight: age=noted, dre=noted, psa=decisive, vol=noted, psad=important, cspca=important, pirads=decisive, comorbidity=important
Sections revealed: radiology_report, psa_trend, laboratory_results, previous_notes
